Wednesday, March 18, 2020
Tuesday, March 17, 2020
#Coronavirus Innovation in #Biotech, #Hemp/ #Cannabis, #Tech Stocks (OTCQB: $SING), (OTCQX: $CRLBF), (NASDAQ: $GILD), (OTC: $CYDY), (NASDAQ: $ZM)
#Coronavirus Innovation in #Biotech, #Hemp/ #Cannabis, #Tech Stocks (OTCQB: $SING), (OTCQX: $CRLBF), (NASDAQ: $GILD), (OTC: $CYDY), (NASDAQ: $ZM)
Entrepreneurism Thrives as SinglePoint Inc. Launches USA Made Hemp Seed Oil Infused Hand Sanitizer
Point Roberts WA, Delta, BC – March 17, 2020 - Investorideas.com, a leading investor news resource covering hemp/ cannabis stocks and coronavirus (COVID-19) stocks issues a snapshot looking at the eruption of innovation in multiple sectors in the face of today’s ongoing pandemic. Crisis has always incited innovation, creating winners and losers and this pandemic is creating a global shift never before witnessed. Companies that are agile enough to adapt and recognize the change can also seize opportunities by providing a definite solution; which is what SinglePoint Inc. (OTCQB: SING) is aiming to do by launching Klen Hands – Hand Sanitizer with Moisturizing Hemp Seed Oil, made in the USA.
Read this news featuring SING in full at https://www.investorideas.com/news/2020/biotech/03171CoronavirusInnovation.asp
On March 13th, Friday the 13th, thought to be an unlucky day by some, SinglePoint Inc. (OTCQB: SING) boldly announced the launch of Klen Hands, yet another example of how they have consistently been on top of consumer and industry trends. Already entrenched in the cannabis and cleantech sectors, during this current crisis, SinglePoint immediately saw the need for a crossover into the health sector as shelves are being emptied of hand sanitizers.
According to the press release: “Hand sanitizer is one of the most out of stock products there is in most all retail locations. We do expect to sell out very quickly. As we move into uncertain times, we have developed a product to directly combat the coronavirus. Our hand sanitizer has 62% ethyl alcohol to keep hands klen (clean) as well as hemp seed oil to keep hands soft and hydrated. Sanitize. Hydrate. Repeat.”
Klen is currently being produced in SinglePoint's Carlsbad facility and will ship directly to your location. Orders will be fulfilled in the order they are received.
"We are working to develop solutions for both product and technology in order to assist in the effort of combating COVID-19. As many people know our company has deep ties to the Washington State area. We believe we can provide solutions in the near term to help with the dissemination of current, reliable information and in the interim use our facilities to develop products such as hand sanitizer. We will be releasing additional resources for individuals in the coming weeks." - Greg Lambrecht CEO.
Another key trend arising in the cannabis space due to the coronavirus outbreak, is the boom of cannabis delivery services. Cresco Labs (CSE:CL)(OTCQX:CRLBF), one of the largest vertically integrated multistate cannabis operators in the United States recently announced the launch of a home delivery service for medical cannabis patients in the New Hartford area of New York.
“Registered medical cannabis patients can place a home delivery order seven days a week at Sunnyside. Shop with a minimum order of $80 required for delivery service. Free delivery is available for orders of $150 or more. Distributed from Cresco’s Sunnyside dispensary in New Hartford, delivery services are available for patients in the following communities: New Hartford, Utica, Marcy, Whitesboro, Oriskany, Clinton, Sauquoit, Frankfurt and Rome.”
Sugarmade, Inc. (OTCQB:SGMD), along with the BudCars Cannabis Delivery Service, announced last week a sharp rise in demand for its cannabis delivery service, driving an associated 10% week-over-week rise in total sales, over the past two weeks. The Company believes this dynamic is being driven by the stay-at-home trend that has emerged in many communities around the world in response to the global pandemic outbreak of the COVID-19 disease.
It looks like there will also be a huge uptick in cannabis sales as consumers are buying and hoarding cannabis just like toilet paper and hand sanitizers.
“Retail stores across the United States have seen an influx of traffic as Americans seek to stock up on basic supplies. Cannabis retailers have seen a similar trend, with many consumers choosing to make fewer trips to dispensaries, instead opting for larger, less frequent purchases as COVID-19 fears grip the country,” reported a Motley Fool correspondent.
In the pharma and biotech sector we have seen players from big to small announce potential solutions as they race to find a vaccine for COVID-19. Gilead Sciences, Inc. (NASDAQ: GILD), a presumed leader, even by the WHO, announced late February the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 (novel coronavirus). These randomized, open-label, multicenter studies will enroll approximately 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, beginning in March. The studies will assess two dosing durations of remdesivir, administered intravenously. The initiation of these studies follows the US Food and Drug Administration’s (FDA) rapid review and acceptance of Gilead’s investigational new drug (IND) filing for remdesivir for the treatment of COVID-19.
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) announced Friday that it plans to evaluate its amniotic fluid concentrate, AmnioBoost, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19).
AmnioBoost has potential for use in the treatment of ARDS, which is the principal cause of death in COVID-19 infection. Mortality in COVID-19 infected patients with the inflammatory lung condition (ARDS) is reported to approach 50%, and is associated with older age, co-morbidities such as diabetes, higher disease severity, and elevated markers of inflammation. Current therapeutic interventions do not appear to improve in-hospital survival.
CytoDyn Inc. (OTC: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the Company has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to conduct a Phase 2 clinical trial with leronlimab (PRO 140) as a therapy for patients who experience respiratory complications as a result of contracting the coronavirus disease 2019 (COVID-19).
Looking at the tech sector, there are multitudes of technology already in place that can be deployed and smart companies are already on it. According to a report from CNBC, “Chinese technology giants are accelerating their efforts in the field of health-care technology in areas from cloud computing to artificial intelligence (AI) amid the new coronavirus outbreak. Alibaba (NYSE: BABA), Baidu (NASDAQ: BIDU), Tencent (OTC: TCEHY), Huawei and DiDi have all launched new health tech features aimed at diagnosing cases and finding a vaccine for the coronavirus.”
Drone technology is also being used for delivery and mapping, and companies like Zoom Video Communications, Inc. (NASDAQ: ZM) are expected to see a boost from all the remote workers.
As we self isolate, social distance and stock up, let’s be smart as investors and not panic and really look at the bigger picture unfolding; innovation and entrepreneurism at its best.
Visit Investorideas.com cannabis and hemp stock directory
Visit Investorideas.com biotech and coronavirus stocks directory https://www.investorideas.com/BIS/stock_list.asp
Visit Investorideas.com tech stocks directory
About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: this article featuring SING is a paid for services on Investorideas.co ( two thousand ) Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Get free investor news alerts
Contact Investorideas.com
800 665 0411
Monday, March 16, 2020
Coronavirus /Biotechnology Stock News Bites - Moderna (NASDAQ: $MRNA)
Coronavirus /Biotechnology Stock
News Bites - Moderna (NASDAQ:
$MRNA) Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA
Vaccine (mRNA-1273) Against Novel Coronavirus
Investorideas.com
(www.investorideas.com) _ Coronavirus
/Biotechnology (COVID-19) Stock News Bites- CAMBRIDGE,
MassModerna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger
RNA (mRNA) therapeutics and vaccines to create a new generation of
transformative medicines for patients, today announced that the first
participant has been dosed in the Phase 1 study of the Company’s mRNA vaccine
(mRNA-1273) against the novel coronavirus (SARS-CoV-2). This Phase 1 study is
being conducted by the National Institutes of Health (NIH) under its
own Investigational New Drug (IND) application.
mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for
a prefusion stabilized form
of the Spike (S) protein, which was selected by Moderna in
collaboration with investigators from the Vaccine Research
Center (VRC) at the National Institute of Allergy and Infectious
Diseases (NIAID), a part of NIH. Manufacture of the first clinical
batch was funded by the Coalition for Epidemic Preparedness
Innovations (CEPI).
The Phase 1 study is evaluating the safety and immunogenicity of
three dose levels of mRNA-1273 (25, 100, 250 μg) administered on a two-dose
vaccination schedule, given 28 days apart. A total of 45 healthy adults will be
enrolled in the study. Participants will be followed through 12 months after
the second vaccination. The primary objective is to evaluate the safety and
reactogenicity of a two-dose vaccination schedule of mRNA-1273. The secondary
objective is to evaluate the immunogenicity to the SARS-CoV-2 S protein.
“This study is the first step in the clinical development of an
mRNA vaccine against SARS-CoV-2, and we expect it to provide important
information about safety and immunogenicity. We are actively preparing for a
potential Phase 2 study under our own IND,” said Tal Zaks, M.D., Ph.D.,
Chief Medical Officer at Moderna. “We are grateful to NIH for
their ongoing collaboration and to CEPI for funding the initial manufacturing
of mRNA-1273 and are proud to be included with the many companies, worldwide
health agencies and NGOs working on a possible response to the novel
coronavirus outbreak.”
On January 11, 2020, the Chinese authorities shared the
genetic sequence of the novel coronavirus. On January 13, 2020 the
VRC and Moderna’s infectious disease research team finalized the sequence for
the SARS-CoV-2 vaccine and Moderna mobilized toward clinical
manufacture. The first clinical batch was completed on February 7,
2020 and underwent analytical testing; it was shipped on February 24,
2020 from Moderna and delivered to NIH from the
Company’s manufacturing facility in 42 days from sequence selection.
Next Steps for mRNA-1273
The Company is actively preparing for a potential Phase 2 study
under its own IND to build on data from the ongoing Phase 1 study being
conducted by the NIH. In order to continue to progress this potential
vaccine during the ongoing global public health
emergency, Moderna intends to work with the FDA and other government
and non-government organizations to be ready for a Phase 2 and any subsequent
trials, which are anticipated to include a larger number of subjects and which
will seek to generate additional safety and immunogenicity data. Manufacture of
the mRNA-1273 material for the potential Phase 2 trial, which could begin in a
few months, is underway. Moderna continues to prepare for rapid
acceleration of its manufacturing capabilities that could allow for the future
manufacture of millions of doses should mRNA-1273 prove to be safe and
effective.
Read the company’s full news and
disclaimer here:
Visit Investorideas.com biotech and
coronavirus stocks directory https://www.investorideas.com/BIS/stock_list.asp
About Investorideas.com
- News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing
third party news, research and original financial content. Learn about
investing in stocks and sector trends with our news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns :
Crypto Corner , Play by Play sports and stock news column,
Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate
Change , Exploring Mining
the AI Eye .
Stock Bites is a branded product of
Investorideas.com Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. This stock bites news release
publication is available as a paid for
service on Investorideas.com https://www.investorideas.com/News-Upload/
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Get free
investor news alerts
Contact Investorideas.com
800 665 0411
Thursday, March 12, 2020
Coronavirus / Diagnostics Stock News Bites: Co-Diagnostics, Inc (NASDAQ: $CODX)
Chief Scientific Officer to Address Bipartisan Commission on Biodefense in Washington, D.C.
Salt Lake City, Utah - March 12, 2020 (Investorideas.com Newswire) Coronavirus / Diagnostics (COVID-19) Stock News Bites: Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Dr. Brent Satterfield PhD, Chief Scientific Officer and co-founder of Co-Diagnostics, will address a meeting held by the Bipartisan Commission on Biodefense in Washington, D.C. on March 18, 2020. The focus of the meeting will be to address national biodefense in light of the response to COVID-19, and its implications for preparedness.
Co-Diagnostics was the first U.S. company to receive a CE-mark for a COVID-19 diagnostic test. The Company is currently shipping orders for its test to countries on 5 continents, including shipments to Italy, the most severely impacted country in the European Union. The Company continues to scale up production to meet global demand, and is also seeking emergency use clearance for use as an in vitro diagnostic by the U.S. FDA as well as by the CDSCO in India, both of which are expected to further increase the domestic and international reach of this powerful and cost-effective diagnostic tool.
The rapid development of the Company's COVID-19 test was made possible by a unique, proprietary design process and patented CoPrimer™ technology platform that was invented by Dr. Satterfield. Prior to founding Co-Diagnostics in 2013, Dr. Satterfield developed new diagnostic platforms for groups such as the Department of Homeland Security, the National Biodefense Analysis and Countermeasures Center, the United States Army Medical Research Institute of Infectious Disease, Sandia National Laboratories, the California Department of Public Health and numerous others.
Dr. Satterfield remarked, "I am pleased to present the details of the rapid development of our COVID-19 test to the Bipartisan Commission on Biodefense. The Company's proprietary platform serves as a template to develop other tests needed now, and in the future as new pathogens surface in our interconnected world. Our current test detects COVID-19 with a high level of specificity to distinguish it from similar viruses. However, in addition to recently being declared a pandemic by the World Health Organization, the virus that causes COVID-19 is also believed to be mutating. Co-Diagnostics' patented CoPrimer technology is uniquely suited to quickly develop multiplex assays that can identify multiple mutations of the virus in a single test when the need arises. Rapid, efficient development of multiplexed tests is a core competency of Co-Diagnostics."
Read the company's full news and disclaimer here:
Visit Investorideas.com biotech and coronavirus stocks directory
About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.
Stock Bites is a branded product of Investorideas.com Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. This stock bites news release publication is available as a paid for service on Investorideas.com https://www.investorideas.com/News-Upload/
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Get free investor news alerts
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences
Like Biotech Stocks? View our Biotech Stocks Directory
Get News Alerts on Biotech Stocks
Wednesday, March 11, 2020
Coronavirus /Biotech Stock News Bites- Tiziana Life Sciences (NASADAQ: $TLSA)
Coronavirus /Biotechnology Stock News Bites
- Tiziana
Life Sciences (NASADAQ: $TLSA) To Expedite Development of its
Fully Human Anti-Interleukin-6-Receptor Monoclonal Antibody, a Potential
Treatment of Certain Patients Infected with Coronavirus COVID-19
Investorideas.com
(www.investorideas.com) _ Coronavirus
/Biotech (COVID-19) Stock News Bites- New York/London, March 11,
2020 - Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS)
("Tiziana" or the "Company"), a biotechnology company
focused on innovative therapeutics for inflammatory and autoimmune diseases,
announced today that it is expediting development of TZLS-501, a
novel, fully human anti-interleukin-6 receptor (anti-IL6R)
monoclonal antibody (mAb) for treatment of patients infected with coronavirus
COVID-19 (SARS-CoV-2). Tiziana plans to
administer TZLS-501 using a proprietary formulation technology. The Company entered into a
world-wide license for composition-of-matter of TZLS-501, a fully human mAb
targeting IL-6R, with Novimmune, SA, a Swiss
biotechnology company in 2017.
Certain patients infected with coronavirus COVID-19 may develop an
uncontrolled immune response ("cytokine storm") resulting in severe
damage to lung tissue which could lead to respiratory failure (see Note 1,
below). Early clinical studies conducted by doctors in China suggest
that anti-IL6R mAbs may be used in clinical practice for treatment of COVID-19.
Consequently, China'sNational Health Commission has recommended
the use of Roche's blockbuster drug, Actemra® for treatment of patients
infected with COVID-19, with serious lung damage and elevated IL-6 levels.
Actemra was first approved by the FDA in 2010 for rheumatoid arthritis. Besides Actemra®, Sanofi
and Regeneron are currently exploring Kevzara®, an FDA-approved anti-IL-6 receptor therapy for rheumatoid arthritis,
for treatment of severe COVID-19.
Tiziana's anti-IL-6R mAb binds to both the membrane-bound
and soluble forms of IL-6R and rapidly depletes circulating levels of IL-6 in
the blood (see Note 2, below). An excessive production of IL-6 is
regarded as a key driver of chronic inflammation and is believed to be
associated with severe lung damage observed with COVID-19 infections and acute
respiratory illness. A recent Chinese study also reported that COVID-19 infection caused clusters of severe respiratory illness such as
severe acute respiratory distress syndrome (ARDS) (see Note 3, below).
"We believe that the features of TZLS-501
consisting of its dual mechanism of action to inhibit signaling by the
membrane-bound and soluble IL-6 receptors along with rapid depletion of
circulating IL-6 cytokine, a major cause of lung damage, provides TZLS-501 with
distinct advantages for treatment of COVID-19 over other anti-IL-6R mAbs such
as Actemra® and Kevzara® for
treatment of COVID-19. The recent decision by
researchers in China to add Actemra® to treatment guidelines for
coronavirus patients with serious lung damage confirms the utility of anti-IL6R
mAb. We are excited to move forward with our clinical development plan to
expedite evaluation in patients as soon as possible", said Dr. Kunwar
Shailubhai, CEO & CSO of Tiziana Life Sciences.
Read the company’s full news and
disclaimer here:
Visit Investorideas.com biotech and
coronavirus stocks directory https://www.investorideas.com/BIS/stock_list.asp
About Investorideas.com
- News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing
third party news, research and original financial content. Learn about
investing in stocks and sector trends with our news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns :
Crypto Corner , Play by Play sports and stock news column,
Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate
Change , Exploring Mining
the AI Eye .
Stock Bites is a branded product of
Investorideas.com Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. This stock bites news release
publication is available as a paid for
service on Investorideas.com https://www.investorideas.com/News-Upload/
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Get free
investor news alerts
Contact Investorideas.com
800 665 0411
Subscribe to:
Posts (Atom)